Connect your AI

MAZE MAZE Net Investment in Lease

Net Investment in Lease at other companies

Vertex PharmaceuticalsVRTX

——

Septerna, Inc.SEPN

——

Stoke Therapeutics, Inc.STOK

——

Olema Pharmaceuticals, Inc.OLMA

——

ZymeworksZYME

——

Nurix Therapeutics, Inc.NRIX

——

Other financials

Income statement

Revenue$20.0M—

Operating income-$26.6M+25.0%

Net income-$24.2M+26.2%

EPS (diluted)-$0.45+60.9%

Balance sheet

Cash & equivalents$198.8M-32.5%

Total debt$61.2M+137%

Total equity$341.7M+17.0%

Total assets$419.7M+26.1%

Cash flow

Operating cash flow-$39.1M-32.5%

CapEx$93.0K-68.9%

Free cash flow-$39.2M-31.5%

Valuation

Market cap$1.48B+201%

Enterprise value$1.34B—

P/S7.9×—

Profitability

Operating margin-71.5%—

Net margin-65.4%—

FCF margin-65.1%—

Returns & leverage

Return on equity-38.7%—

Debt / equity0.2×+0.1×

Current ratio17.9×+1.8×

Where this comes from

Reported directly by MAZE in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is MAZE's net investment in lease?: MAZE (MAZE) reported net investment in lease of $19.29M in Q1 2026.
How has MAZE's net investment in lease changed year-over-year?: MAZE's net investment in lease decreased by 14.2% year-over-year, from $22.48M to $19.29M.